GlassScriptPhysician profile
Kenneth L Blad
NPI 1285609685
$6,220.28
in general payments reported to CMS, 2019-2025
57 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $339 · 2021: $859 · 2022: $833 · 2023: $1,222 · 2024: $993 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.94 | 2019-2025 | Qulipta, Viberzi, Ubrelvy |
| Novo Nordisk INC | $764.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $646.68 | 2019-2025 | Breztri, Bevespi Aerosphere, Airsupra |
| Otsuka America Pharmaceutical, INC. | $476.01 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $441.98 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $285.44 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $242.69 | 2022-2025 | |
| Pfizer INC. | $229.85 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $221.02 | 2019-2025 | Invega Sustenna, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.83 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $158.13 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $155.29 | 2019-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $102.04 | 2024-2025 | Gemtesa |
| Medtronic, INC. | $101.19 | 2021-2025 | Symplicity G3, Venaseal |
| Abbott Laboratories | $87.10 | 2023-2025 | Freestyle Libre 3, Eterna, Freestyle Libre 2 |
Show all 54 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Blad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.